BU researcher named Class of 2025 Fellow of American Society for Pharmacology and Experimental Therapeutics
Grant and Award Announcement
Updates every hour. Last Updated: 7-Jun-2026 03:15 ET (7-Jun-2026 07:15 GMT/UTC)
Venetia Zachariou, PhD, Edward Avedisian Professor and chair of pharmacology, physiology & biophysics at Boston University Chobanian & Avedisian School of Medicine, has been named a Class of 2025 Fellow of the American Society for Pharmacology and Experimental Therapeutics (ASPET). Selection as a Fellow is an honor bestowed to the most distinguished members of the organization. Fellows are recognized for their meritorious efforts to advance pharmacology, through their scientific achievements, mentorship and service to the Society. Zachariou is one of 17 new Fellows.
Cardiovascular disease remains a major concern in cities, with poor outcomes and high societal cost often driven by unequal access to healthcare.
A pan-European consortium of 34 international partners launches an ambitious project to reduce the burden of urban cardiovascular disease.
The initiative will focus on obesity, high blood pressure, elevated cholesterol and diabetes, which are common yet treatable causes of death, heart disease, stroke and vascular dementia.
Researchers report that redesigning neurokinin-1 receptor (NK1R) antagonists can restore antidepressant-like effects in animal models. Using machine-learning-guided screening, the team identified structurally distinct compounds that lack chemical features found in earlier failed drugs. In mouse models of stress- and inflammation-induced depression, the lead compound reduced depressive-like behavior and brain inflammation without affecting locomotion. The findings suggest that NK1R remains a viable therapeutic target when approached with improved molecular design.
CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations associated with the strategy, including off-target DNA editing. A group of researchers from Japan has explored a novel strategy involving CRISPR–Cas3 and investigated its potential using a mouse model of transthyretin amyloidosis (ATTR). The results highlight its potential as an efficient genome-editing system. The technology can be developed as a therapeutic strategy for treating ATTR and other genetic disorders.
Infertility is a major healthcare concern. Understanding the molecular regulators governing fertilization, early embryonic development, and implantation is crucial for the success of assisted reproductive technologies. Now, researchers from Kanazawa Medical University integrated one-cell embryo cryopreservation technology, inhibitor library screening, RNA-seq analysis, and CRISPR-Cas9-mediated gene editing to identify eleven novel factors essential for the development of fertilized eggs. The study contributes towards a better understanding of the underlying mechanisms.
Fluorescent dyes enable the visualization of biomolecular localization and dynamics in living systems. To date, no single benzene-based fluorophores with absorption and emission at wavelengths above 600 nm, the ideal wavelength for bioimaging, have been developed. To address this challenge, researchers from Japan have developed bis-pseudoindoxyls. Owing to its unique red-shifted absorption and fluorescence properties, this dye holds promise for applications in red-light-based bioimaging studies.